Pathology: non squamous - mNSCLC - L1 - all population; non squamous - mNSCLC - L1 - Wild Type (WT);
non squamous - mNSCLC - L1 - all population | non squamous - mNSCLC - L1 - Wild Type (WT) | |||||||||
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 | IMpower-130 (all population), 2019 | IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 | IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 | IMpower-150 (ABCP vs BPC WT), 2018 | IMpower-130 (WT), 2019 | IMpower-132 (WT), 0 | KEYNOTE-021, 2016 | KEYNOTE-189, 2018 | ||
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | 3 | T1 | T1 | T1 | ||||||
atezolizumab plus carboplatin plus nab-paclitaxel | 2 | T1T0 | T1 | |||||||
atezolizumab plus pemetrexed and platin | 1 | T1 | ||||||||
atezolizumab plus carboplatin plus paclitaxel | 1 | T1 | ||||||||
pembrolizumab plus SoC | 1 | T1 | ||||||||
pembrolizumab and pemetrexed plus platin | 1 | T1 | ||||||||
carboplatin plus nab-paclitaxel | 0 | T0 | ||||||||
pemetrexed plus platin | 0 | T0 | T0 | |||||||
bevacizumab plus carboplatin and paclitaxel | 0 | T0 | T0 | T0 | T0 | |||||
placebo plus SoC | 0 | T0 |